Get CardioSmart !!

By
Sheree Schroeder, MSN, RN, RDCS, FASE
Indiana CCA Liaison
Director of Quality Review Services
Accreditation for Cardiovascular Excellence
CardioSmart is the ACC patient education and empowerment initiative brought to you by the American College of Cardiology. Our mission is to help individuals prevent, treat and manage cardiovascular disease. You will learn more about ACC CardioSmart product from our next speaker. I am going to discuss with you today how you can stay “cardio smart”.
OK Where do we as CV Team Members Find Reliable Information?
– ACC- Is Your Professional Organization
  • Cardiosource.org
  • CardioSmart.org
– Attend State and National Scientific Meetings
– ACCN
– ANA
– Medscape.com
  • “Ending Opioid Abuse-What Clinicians Can Do”
– MedPage Today-Medpagetoday.com
So What’s the Buzz in Cardiology?

Niacin
PCSK-9
Treatment Goals for Lipids?
Stem Cells
TVAR
TCT-Renal Artery Denervation Still Alive
Radials
Femoral Closure Devices
Accreditations for CCls
Team Based Approach Best with Everything
Niacin treatment did not reduce the primary end point across tertiles of any baseline lipid parameters.
AMG-145 is a fully human monoclonal antibody to PCSK-9, the natural inhibitor of the LDL receptor. The drug lowers LDL-C and maximizes the potential benefit of statins. Clinical trials are ongoing with at least two PCSK-9 inhibitors, including one that is a clinical outcome study. While requiring an injection biweekly or monthly, the absence of side effects and adverse events in the early studies makes this a very attractive lipid-lowering drug for resistant hypercholesterolemia, and has the potential to reduce the ‘residual risk’ in coronary heart disease patients on maximal doses of statins.
In phase 1 studies, (18 months ago) AMG 145 significantly reduced serum LDL-C in healthy and hypercholesterolemic statin-treated subjects, including those with heterozygous familial hypercholesterolemia or taking the highest doses of atorvastatin or rosuvastatin, with an overall AE profile similar to placebo.
Now

Phase III- Odyssey Mono-July 2014
- 1 cc injection 75 mg every two weeks
  - 47-54% reduction
  
  LDL below 70 is non atherogenic

http://biomarkers.cardiosource.org/Video-News/Video/2014-July-First-Phase-3-Data-Being-Reported-for-a-PCSK9-Inhibitors.aspx
Lipid Targets?

There is no evidence to support continued use of specific LDL-C and/or non–high-density lipoprotein cholesterol (non–HDL-C) treatment targets. The appropriate intensity of statin therapy should be used to reduce risk in those most likely to benefit.
Stem Cells

Stem Cell Research at Stanford
Capabilities to Re-assign Stem Cells
Pluripotent Stem Cells-Embronic Induced PSC-(IPSC) 2 wks
Genome Editing of Isogenic IPSCs

Joewu@stanford.edu
TAVR

It is Here to Stay!
High Value- 50 K
(Medical Therapy does not work for AS)
New Valves
Radials

Here to Stay

Cost Effective

Safer

Patient Satisfier
TCT 2014 Wrap-up!

Renal Artery Denervation Lives
Partner I Trial-5 year follow-up 😊
1 year vs 2.5 year survival
Asorb II
Femoral Artery Closure
Vs
Manual Pressure
What’s New with ACE?

DX and PCI
Carotids
CHD
PVD
TAVR
EP
Team Based Approach

Patient Care
Mitigating Financial Risk
Documentation
Patient Education
Lobbying
In Summary - Be Exceptional
Be CardioSmart!

Education - Life Long Learning
Professional Societies - Stay Connected
Mentoring
Networking
Attitude
Make a Difference!
References:

http://www.cardiosource.org
How can ACC better serve you?